Table 1.

Baseline characteristics of the patients who reached the primary end-point (day 28)

		Quinine	Atovaquone/Proguanil	Artemether/Lumefantrine
n		30	30	30
sex	m/f	16/14	16/14	18/12
age	range	6 – 50	6 – 35	8 – 40
	mean	19.2	19.9	18.1
	median	16	18	17
Temperature (C°)	range	36.0 – 39.5	36.0 – 39.3	35.6 – 39.9
	mean	37.4	37.3	37.5
	median	37.2	37.3	37.4
Parasitaemia	range	360 – 63,000	400 – 69,880	480 – 83,600
	mean	15,469	13,028	21,189
	median	6,740	4,960	9,300
Symptoms	Headache	30	30	30
	Nausea/vomiting	21	17	22
	Shivering	23	26	21
	Diarrhea	4	2	3
Actual daily dose (mg/kg)	range	30.5 – 36	15 – 23	2.3 – 4.6
	mean	34.9	19.5	3.4
	stdev	1.6	1.9	0.6

Baseline patients' characteristics of the patients who reached the primary end-point (day 28) were not significantly different between the three treatment groups in respect to age (Kruskal-Wallis-test, p = 0,504), sex (χ²-test, p = 0,835), parasitaemia (Kruskal-Wallis-test, p = 0,444), body temperature (Kruskal-Wallis-test, p = 0,860). There is also no significant difference in these baseline characteristics of the treatment groups when comparing all 97 treated patients.